![](https://cdn.benzinga.com/files/biokin.jpg?width=1200&height=800&fit=crop)
Sichuan Biokin Chases Hong Kong Listing After BSM Drug Deal
Key Takeaways: Sichuan Biokin has been using proceeds from generic drug sales to develop novel oncology drugs, but government procurement policies in China have slowed its revenue stream while R&D spending is on the rise The company has put six ADCs …